Luc Brunsveld (1975) is chemical biologists specialized in protein-protein interactions and drug discovery. He obtained a PhD in 2001 with Prof. Bert Meijer from Eindhoven University of Technology. Subsequently, he was postdoctoral fellow with Prof. Herbert Waldmann at the Max-Planck Institute of Molecular Physiology (MPI, Dortmund, Germany) working on Rab and Ras protein semi-synthesis. After that, he was group leader in medicinal chemistry at Organon (Oss, the Netherlands, now Merck). In 2005, he started a research group at the MPI in Dortmund, working on supramolecular chemical biology, and subsequently also became group leader at the Chemical Genomics Centre of the Max Planck Society, working on protein-protein interactions. In 2008, he moved to TU/e where he was appointed Full Professor of Chemical Biology in the Department of Biomedical Engineering. His current research involves developing novel drug discovery concepts for “undruggable” proteins and drug discovery within biomolecular condensates.
Brunsveld has received numerous appealing grants, among which ERC Starting, Proof of Concept, and Advanced grants (2008, 2010, and 2023 respectively) and the NWO Vici grant (2015). He was awarded the NVBMB Award of the Dutch Society for Biochemistry and Molecular Biology in 2010. the Gold Medal of the Royal Netherlands Chemical Society KNCV in 2013, and the Leadership in Excellence Award from the TU Eindhoven (2023). In 2022 Luc was elected as member of the KNAW (Royal Dutch Academy of Sciences). Together with Christian Ottmann (TU/e) and Michelle Arkin (UCSF), he is co-founder of Ambagon Therapeutics.